Pharmacokinetics, Short-term Safety and Efficacy of the Approved Once-daily Darunavir/Ritonavir Dosing Regimen in HIV-infected Children
Fulltext:
196133.pdf
Embargo:
until further notice
Size:
78.23Kb
Format:
PDF
Description:
Publisher’s version
Publication year
2018Source
Pediatric Infectious Disease Journal, 37, 10, (2018), pp. 1008-1010ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Clinical Pharmacy
Paediatrics
Laboratory Medicine
Journal title
Pediatric Infectious Disease Journal
Volume
vol. 37
Issue
iss. 10
Page start
p. 1008
Page end
p. 1010
Subject
Radboudumc 4: lnfectious Diseases and Global Health RIHS: Radboud Institute for Health Sciences; Radboudumc 4: lnfectious Diseases and Global Health RIMLS: Radboud Institute for Molecular Life Sciences; Clinical Pharmacy - Radboud University Medical Center; Paediatrics - Radboud University Medical CenterAbstract
In this multicenter pharmacokinetic study in HIV-infected children (6-12 years of age), we validated the approved once-daily darunavir/ritonavir dosing recommendations. The geometric mean darunavir area under the plasma concentration-time curve was 63.1 h.mg/L, substantially lower than the mean value observed in adults. However, all trough levels were adequate, and short-term virologic outcome was good. These data support the use of the darunavir/ritonavir once-daily dosing recommendations.
This item appears in the following Collection(s)
- Academic publications [245396]
- Electronic publications [132943]
- Faculty of Medical Sciences [93203]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.